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Transplantation of several types of stem cells (SC) for the treatment of amyotrophic lateral sclerosis (ALS) has been evaluated in
numerous Phase I/II clinical trials with inconclusive results. Here, we conducted a meta-analysis to systematically assess the
outcome of SC therapy trials which report the evolution of each patient before and after cell administration. In this way, we aimed
to determine the effect of the SC intervention despite individual heterogeneity in disease progression. We identified 670 references
by electronic search and 90 full-text studies were evaluated according to the eligibility criteria. Eleven studies were included
comprising 220 cell-treated patients who received mesenchymal (M) SC (n= 152), neural (N) SC (n= 57), or mononuclear cells
(MNC: CD34, CD117, and CD133 positive cells) (n= 11). Our analyses indicate that whereas intrathecal injection of mesenchymal
stromal cells appears to have a transient positive effect on clinical progression, as measured by the ALS functional rating score,
there was a worsening of respiratory function measured by forced vital capacity after all interventions. Based on current evidence,
we conclude that optimal cell product and route of administration need to be determined in properly controlled preclinical models
before further advancing into ALS patients. In addition, in-depth understanding of disease mechanisms in subsets of patients will
help tailoring SC therapy to specific targets and increase the likelihood of improving outcomes.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
with a largely unknown pathogenesis that primarily targets motor
neurons. Recent studies report a prevalence between 4.1 and 8.4
per 100,000 persons, with the male-to-female ratio being between
1 and 2. The mean age at diagnosis is 54–69 years and patients
manifest weakness in the limbs (spinal onset) or difficulty in
speaking or swallowing (bulbar onset) that leads to death, usually
through respiratory failure, 24–50 months after the diagnosis1.
About 10% of ALS cases are familial (FALS), caused by dominantly
inherited autosomal mutations in SOD1, TARDBP, FUS, and C9orf72,
among other genes2. Mutations in these genes, which also occur in
sporadic forms of the disease, alter proteostasis, protein trafficking
and quality control, perturb aspects of RNA stability, function and
metabolism, nuclear pore transport, and cytoskeletal dynamics3.
Neuropathological findings include degeneration and loss of
motoneurons with astrocytic gliosis in the motor cortex, the
brainstem, and the spinal cord, and, in most cases, ubiquitinated
cytoplasmic TDP-43 inclusions. Besides, other pathogenic pro-
cesses, such as glutamate toxicity, endoplasmic reticulum and
oxidative stress, loss of trophic factors, inflammation, or mitochon-
drial dysfunction have been involved in disease onset and
progression, based on experimental and clinical data4.
Despite much research, there has been little success in the quest for
disease modifying or neuroprotective strategies, with only two FDA-
approved pharmacological agents, riluzole and edaravone. Around
40% of SOD1 ALS patients have hyperexcitability and this correlates
with a more severe outcome. Indeed, riluzole (2-amino-6-[trifluor-
omethoxy] benzothiazole, RP54274), the standard of care in ALS, is an
antagonist of glutamatergic neurotransmission that has been
demonstrated to slightly delay the onset of respiratory dysfunction
and extend the median survival 2–3 months5. Edaravone (MCI-186,
3-methyl-1-phenyl-2-pyrazolin-5-one) is a strong antioxidant that has
been recently shown to slow down the decline of ALS functional
rating score (FRS) compared with placebo6. In addition, clinical trials
are underway with antisense oligonucleotides targeting mutations in
SOD1 (NCT02623699)7 and C9orf72 (NCT03626012)8 genes.
Stem cell (SC) therapy has been proposed as a promising
treatment option for ALS based on the potential effects on various
pathogenic mechanisms through trophic and/or immunomodula-
tory support and, perhaps, by providing host neural cell
replacement9. Indeed, in the past two decades, transplantation
of various SC products has been evaluated in numerous Phase I
and II clinical trials designed to assess feasibility and safety, but
also looking for indications of clinical benefit, reflected by changes
in the progression rate of the ALS functional ratings score
(ALSFRS) and the respiratory function (forced or slow vital
capacity, F/SVC). Regarding efficacy, results are mostly incon-
clusive due to the limited sample size of the trials and the
heterogeneity of individual progression. In addition, very few trials
are controlled, as inclusion of adequate sham controls for invasive
procedures is problematic and often unethical. Therefore, we
decided to conduct a meta-analysis of SC trials considering all
clinical trials that report the evolution of each patient before and
after cell administration. In this way, we aimed to determine the
efficacy of the SC administration despite individual heterogeneity.
RESULTS
Selection of studies
We systematically searched for references related to clinical trials
using cell therapy in patients with ALS (Supplementary Table 1).
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We identified 670 references by electronic search and 90 full-text
studies were evaluated according to the eligibility criteria.
Eligibility criteria included reporting numerical data for ALSFRS
and/or FVC at least for three time points: tpre, at ≥3 ± 0.5 months
before the intervention, t0, at the time of the intervention (0 ≤
0.5 months), and tpost, at ≥3 months following the intervention, in
order to calculate the scores for the lead-in and follow-up periods.
Finally, 13 studies accomplished all eligibility criteria (Fig. 1a).
Following risk of bias assessment using the tool for non-
randomized studies (RoBANS)10, another two studies11,12 were
excluded due to a high risk of bias; only one study13 showed low
risk for the six domains of RoBANS (Fig. 1b). Thus, 11 publica-
tions13–23 were included in the meta-analysis of which one was
controlled17 and another one used historical controls21 in the
analysis. The studies comprised 220 cell-treated patients who
received mesenchymal (M) SCs (n= 152), neural (N) SCs (n= 57),
or mononuclear cells (MNCs), which include CD34-, CD117-, and
CD133-positive cells (n= 11). Cell dose and administration
frequency varied among studies. The administration routes were
intrathecal (six studies), intrathecal + intramuscular (one study),
intravascular (one study), or intraspinal (five studies) (Table 1).
Inclusion and exclusion criteria for the individual clinical trials are
summarized in Supplementary Table 2. Mean baseline scores
differed across individual studies, for ALSFRS-R, from 24.8 to 39.85
and for FVC, from >50% to 106%; (Supplementary Table 3).
Effect of SC therapy on clinical score
We first analyzed the evolution of patients included in each study,
before and after cell administration comparing the score change
for ALSFRS-R, in points per month (Table 2). Overall, MSC
administration did not have a significant effect on ALSFRS-R
decline rate, but with highly significant subgroup differences at all
times examined. ALSFRS-R decline was significantly slower when
the MSCs were injected intrathecally14–18 but not by intraspinal19
injection. The intravascular route18 was associated with a faster
ALSFRS-R deterioration at all time points. The effects from forest-
plot analysis of individual studies using MSCs are shown in Fig. 2a.
The analysis of three NSC20–22 and one MNC23 studies showed
that the intraspinal administration did not have a significant effect
on ALSFRS-R decline rate (Table 2). Regarding NSC injection, not all
the patients included in two of the trials20,21 had sufficient data to
calculate the scores for the lead-in period and were excluded. It is
also important to note that the number of included patients
treated with MNCs was very small. The effects from forest-plot
Fig. 1 Meta-analysis design. a Selection of studies. b Risk of bias summary: authors’ judgment about each risk of bias item for the included
studies. Red: high; yellow: unclear; green: low, according to RoBANS criteria10.
C. Morata-Tarifa et al.
2













analysis of individual studies using NSCs are shown in Fig. 2b.
These were all administered by direct injection into the
spinal cord.
Effect of SC therapy on pulmonary function
FVC decline was significantly faster in the post-treatment period
compared with the lead-in period for patients treated with
MSCs (Table 3). Subgroup analysis showed that the administra-
tion of MSCs by intrathecal route14–18 at 3, 6, and 18 months, by
intraspinal19 route at 24 months, or by intravascular route18 at
all times was associated with a faster FVC decline. Intriguingly,
the intrathecal + intramuscular (biceps and triceps) adminis-
tration15 of MSCs in 14 patients was associated with an
improvement in the FVC post-treatment, but we did not have
access to the raw data for this study. The effects on FVC from
forest-plot analysis of individual studies using MSCs are shown
in Fig. 3a. FVC decline was significantly steeper at 3 and
6 months post-treatment compared with the lead-in period in
patients infused with NSCs20–22 as well (Fig. 3b). Patients
infused with NSCs showed an improvement at later times, but
this was probably influenced by the loss of most severe patients
(Table 3). A similar pattern was observed in patients infused
with MNCs23 (Table 3).
To rule out publication bias, we performed funnel plots. Egger’s
test showed no asymmetry indicative of publication bias for the
MSC studies: P= 0.5 for ALSFRS (k= 8) and P= 0.78 for FVC (k= 6)
at 3 months. For the NSC meta-analysis, inspection of the funnel
plot distribution did not support a correlation between the effect
size and the sample (Egger’s test neither showed a significant
asymmetry, P= 0.55 for ALSFRS and P= 0.27 for FVC, but with
only three studies regression lacks sensitivity).
Subgroup analyses
Given that the meta-analysis revealed strong effect of subgroups,
but because of the heterogeneity of trial designs we could not
compare each condition side by side, we decided to perform
additional two-way analyses of variance to examine the effects
of the cell product and the route of administration on the
progression of ALSFRS-R and FVC, using the slopes calculated from
all available scores for the lead-in period and the follow-up of
individual studies (Supplementary Fig. 1).
Regarding the cell product—and taking into account that there
were highly significant differences between the studies within the
three groups, i.e. MSC, NSC, and MNC (P= 0.0034)—we found no
significant effect on the ALSFRS-R slopes. There was neither a
significant effect of the cell product on the FVC slopes, but in this
case we could detect a significant effect of time (P= 0.028) with
significant differences in the MSC group between the slopes in the
lead-in period and the follow-up at 3–4 months (P= 0.043) and at
12 months (P= 0.03) (Fig. 4a).
We next examined the effect of the route of administration on
ALSFRS-R, and detected a significant effect of the route (P=
0.0508) with significant interaction of time and route (F6,27=
3.163, P= 0.0176) but no significant differences within groups in
Table 1. Clinical trials included in the meta-analysis.
Study Patients (n) Cell type Flow cytometry Dose: cells × 106 × times Administration route
Kim et al.13 Non-responders: 18 BM-MSC CD29+, CD44+, CD49+, CD73+,
CD105+
CD34−, CD45−




Oh et al.14 7 BM-MSC CD29+, CD44+, CD49+, CD73+,
CD105+
CD34−, CD45−
1/kg × 2 (1 month
apart) in CSF
Intrathecal (L2–L4)





14 Low dose: 1+ 1 × 24
Mid dose: 1.5+ 1.5 × 24
High dose: 2+ 2 × 24
Intrathecal + Intramuscular
Syková et al.16 26 BM-MSC CD73+, CD90+, CD105+
CD34−, CD45−
15 ± 4.5 (single) Intrathecal (lumbar)
Oh et al.17 Treated: 32 BM-MSC CD29+, CD44+, CD73+, CD105+
CD34−, CD45−




Nabavi et al.18 8 BM-MSC CD44+, CD73+, CD90+, CD105+
CD34−, CD45−
2/kg in NaCl + alb 2% Intrathecal
6 2/kg in NaCl + alb 2% Intravenous
Mazzini et al.19 10 BM-MSC CD29+, CD44+, CD90+, CD105+,
CD106+, CD166+
CD34−, CD45−
74.64 (11.4–120) in CSF Intraspinal (T4–T6)
Feldman
201420
15 Fetal NSC NSI-566RSC 0.5 × 5 (unilateral/bilateral) Intraspinal (C3–C5; L2–L4)
Glass et al.21 9 Fetal NSC NSI-566RSC 0.5–1.5 × 5 (unilateral)
1 × 5 (bilateral)
Intraspinal (C3–C5; L2–L4)
15 2 × 5 (bilateral)
4–8 × 10 (bilateral)
16 × 10 (bilateral) × 2
Intraspinal
(C3–C5; L2–L4)
Mazzini et al.22 18 Fetal NSC – 0.75 × 3 (unilateral/bilateral) Intraspinal (C3–C5; T8–T11)
Blanquer
et al.23
11 BM-MNC CD34+, CD117+, CD133+ – Intraspinal
(T3–T4)
BM bone marrow, MSC mesenchymal stromal cells, NTF Neurotrophic factor, CSF cerebrospinal fluid, alb albumin.
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the post-hoc analysis. On the other hand, the effect of the route
on the FVC was significant (F2,7= 8.07, P= 0.015) showing a faster
progression for all routes, with a highly significant effect of time
and a significant interaction of time and route. In the post-hoc
analysis, the differences between the slopes for the lead-in period
and the follow-up were significant at 12 months for intrathecal,
P= 0.025 and showed a trend for intraspinal, P= 0.09. The post-
hoc analysis also showed a difference between 3 and 12 months
for the intraspinal route (P= 0.05) but in the opposite direction
(improvement) (Fig. 4b), consistent with the forest-plot results.
Adverse events
Finally, although all included studies were considered to be safe,
we examined the adverse events (AEs) related to the intervention,
as a relevant aspect in risk-management for cell therapies. AEs
are presented in Supplementary Table 4. Most common AEs were
general disorders and events related with the administration site
(45.05 % [91/202]), nervous system disorders (40.1% [81/202]), and
musculoskeletal and connective tissue disorders (19.3% [39/202]).
We further analyzed the frequency of AEs by route of adminis-
tration (Supplementary Fig. 2). Two trials with intraspinal NSC
injections reported serious AEs related to the treatment. In the
first, a Phase I study20, three patients out of six reported wound
dehiscence (n= 1), incisional (n= 2) and neck (n= 1) pain, and
headache (n= 1) that were resolved. In the second, a Phase II
trial21, one of the patients experienced neurologic deterioration
due to acute spinal cord swelling, and another one suffered
neuropathic pain. Importantly, none of these were completely
resolved.
Table 2. Differences in ALSFRS-R change, in points per month, between the lead-in and follow-up periods.
3–4 Months 6 Months 12 Months 18 Months 24 Months
MSC
Intrathecal
Patients (n) 95 57 17 8 NA
Subtotal (95% CI) 0.72 (0.12, 1.32) 0.92 (0.44, 1.40) 0.44 (−0.39, 1.26) 0.91 (0.09, 1.73) NA
Test for overall effect; Z= 2.36 P= 0.02 Z= 3.74 P= 0.0002 Z= 1.04 P= 0.30 Z= 2.17 P= 0.03 NA
Heterogeneity I2= 90% I2= 69% I2= 60% NA
Intrathecal + intramuscular
Patients (n) NA 14 NA NA NA
Subtotal (95% CI) NA 0.80 NA NA NA
Test for overall effect; NA NA NA NA NA
Heterogeneity
Intravascular
Patients (n) 5 5 5 NA NA
Subtotal (95% CI) −1.08 (−1.57, −0.59) −1.76 (−2.66, −0.86) −1.28 (−1.85, −0.71) NA NA
Test for overall effect; Z= 4.32 P < 0.0001 Z= 3.84 P= 0.0001 Z= 4.41 P < 0.00001 NA NA
Heterogeneity NA NA NA
Intraspinal
Patients (n) 10 10 9 9 7
Subtotal (95% CI) −0.2 (−0.93, 0.53) −0.02 (−0.53, 0.49) −0.04 (−0.50, 0.42) −0.32 (−0.82, 0.18) −0.22 (−0.87, 0.43)
Test for overall effect; Z= 0.54 P= 0.59 Z= 0.08 P= 0.94 Z= 0.17 P= 0.86 Z= 1.25 P= 0.21 Z= 0.67 P= 0.51
Heterogeneity NA NA NA NA NA
Total
Patients (n) 110 72 31 17 NA
Total (95% CI) 0.37 (−0.29, 1.03) 0.28 (−0.48, 1.04) −0.14 (−0.99, 0.71) 0.25 (−0.90, 1.45) NA
Test for overall effect Z= 1.11 P= 0.27 Z= 0.74 P= 0.46 Z= 0.32 P= 0.75 Z= 0.41 P= 0.68 NA
Test for subgroup differences P < 0.0001 P < 0.00001 P= 0.0004 P= 0.01 NA
NSC
Intraspinal
Patients (n) 30 29 21 2 NA
Total (95% CI) 0.07 (−1.43, 1.57) 0.19 (−0.35, 0.74) 0.15 (−0.33, 0.62) 0.00 (−1.11, 1.11) NA
Test for overall effect; Z= 0.09 P= 0.93 Z= 0.70 P= 0.49 Z= 0.61 P= 0.54 Z= 0.00 P= 1.00 NA
Heterogeneity I2= 74% I2= 2% I2= 13% NA
MNC
Intraspinal
Patients (n) 11 11 9 NA NA
Total (95% CI) 0.47 (−0.39, 1.33) 0.56 (−0.30, 1.42) 0.41 (−0.41, 1.23) NA NA
Test for overall effect; Z= 1.07 P= 0.29 Z= 1.28 P= 0.20 Z= 0.98 P= 0.33 NA NA
Heterogeneity NA NA NA
NA not applicable.
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DISCUSSION
SC therapy is viewed as a promising option for ALS because these
cells potentially target several of the putative pathogenic
mechanisms involved in the onset and progression of the disease,
although explicit target engagement for each cell product needs
further validation9. Here, we designed a meta-analysis to examine
individual progression as a measure of efficacy, using the ALSFRS-
R change, which is considered to be linear for the majority of the
illness24 Overall, and with the limitations that are discussed below,
we found that, based on current evidence, cell therapy has a
transient positive effect on the progression of the disease, as
measured by the ALSFRS-R. In the available controlled studies that
we reviewed (76 patients receiving MSCs or MNCs), there was also
a trend for a better progression in patients receiving cell therapy.
In those studies, the administration of MSCs was intrathecal17 or
intrathecal + intramuscular25, and intracortical for MNCs26.
In our meta-analysis, the effect of the SC therapy on ALSFRS-R
was not huge when considering the monthly score but, if
sustained, the cumulative effect could represent a meaningful
clinical change at 6 months and later. For context, note that the
difference at 6 months for the FDA-approved antioxidant
edaravone over placebo was 2.41 points in a selected cohort27,
or ~0.41 points per month. Additional considerations need to be
made because (1) some studies reported a very short follow-up,
(2) patients included in some of these trials were in an advanced
stage (and this precluded us to analyze the effect on survival)
and, (3) long-term changes, although encouraging, need to be
interpreted with caution and are more difficult to associate with
the intervention due to loss of the most severe patients during the
study. Notwithstanding, the clinical data supports a positive effect
of the intervention on the progression of the symptoms, if
transient.
We also examined the effect on FVC, as a value less likely to be
biased. However, and unlike ALSFRS-R, the progression of FVC has
been shown to follow distinct trajectories28, so the comparison of
pre- and post-treatment FVC slopes maybe less informative with
respect to the effect of the intervention. Also, the slope calculation
was less accurate as there were fewer values reported and fewer
Fig. 2 Effect of SC therapy on clinical score. Forest-plots of the changes in ALSFRS-R, in points per month, between the lead-in period and
the follow-up [(score at tx post− score at t0)/x] minus [(score at t0− score at tX pre)/x], evaluated at different follow-up time points, in patients
infused with a MSCs or b NSCs. Squares and black lines represent the mean differences and 95% CI of individual studies and the different
colors stand for the follow-up times, as indicated in the legend.
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studies reporting values. Nevertheless, we cannot ignore that,
overall, there was a worsening of FVC values after the intervention
that was pronounced early on. The most plausible interpretation is
that the intervention disrupts a delicate respiratory functional
balance, being, in that regard, not different from other surgical
interventions that appear to accelerate the progression of
ALSFRS29. However, this is an unlikely explanation for the
intrathecal administration, which is a minor procedure and did
not cause significant worsening in a controlled study27 raising
questions about potential MSC off-target effects. Indeed, in the
controlled study27, the authors reported that the FVC progression
in points per month was not significantly different between
controls (−0.8 ± 3.18, n= 25) and MSC-treated patients (−1.54 ±
3.38, n= 31) with respect to their lead-in periods, i.e. a difference
of −0.74 (−2.52, 1.03) points per month in favor of controls, but
note that MSC-treated patients showed a significant worsening in
the follow-up period with respect to the lead-in (P= 0.023) while
controls did not (P= 0.29). On the other hand, for intraparench-
ymal interventions, the effect of the SC treatment on ALSFRS-R
could be larger if compared with a sham procedure, emphasizing
the inadequacy of non-interventional controls and the need to
investigate these issues in properly controlled preclinical models.
The source and class of the cells to be transplanted represent an
arguable point for the implementation of cell therapy in central
nervous system (CNS) disorders. Most clinical trials—and all the
intrathecal ones—included in this meta-analysis were performed
with autologous Bone marrow mesenchymal stromal cells (BM-
MSCs). These trials presented some differences regarding cell
preparation, cell dose, and administration regime and, overall,
those using intrathecal repeated administration in cerebrospinal
Table 3. Differences in FVC change per month between the lead-in and follow-up periods.
3–4 Months 6 Months 12 Months 18 Months 24 Months
MSC
Intrathecal
Patients (n) 66 28 24 11 NA
Subtotal (95% CI) −1.68 (−2.40, −0.96) −1.26 (−1.91, −0.60) −0.90 (−1.87, 0.07) −1.19 (−1.76, −0.62) NA
Test for overall effect;
Heterogeneity
Z= 4.57 P <0.00001 Z= 3.78 P= 0.0002 Z= 1.81 P= 0.07 Z= 4.10 P <0.0001 NA
I2= 0% I2= 0% I2= 73% NA
Intrathecal + intramuscular
Patients (n) NA 14 NA NA NA
Subtotal (95% CI) NA 3.46 NA NA NA
Test for overall effect;
Heterogeneity
NA NA NA NA NA
Intravascular
Patients (n) 5 5 NA NA NA
Subtotal (95% CI) −3.92 (−6.59, −1.25) −5.12 (−7.14, −3.10) NA NA NA
Test for overall effect;
Heterogeneity
Z= 2.88 P= 0.004
NA




Patients (n) 10 9 9 8 7
Subtotal (95% CI) −1.46 (−4.18, 1.26) −0.34 (−1.65, 0.97) −1.00 (−2.27, 0.27) −0.79 (−1.97, 0.39) −1.08 (−2.05, −0.11)
Test for overall effect;
Heterogeneity
Z= 1.05 P= 0.29
NA
Z= 0.51 P= 0.61
NA
Z= 1.54 P= 0.12
NA
Z= 1.32 P= 0.19
NA
Z= 2.18 P= 0.03
NA
Total
Patients (n) 81 42 33 19 NA
Total (95% CI) −1.81 (−2.49, −1.14) −2.07 (−3.81, −0.32) −0.95 (−1.61, −0.29) −1.11 (−1.63, −0.60) NA
Test for overall effect Z= 5.26 P < 0.00001 Z= 2.32 P= 0.02 Z= 2.83 P= 0.005 Z= 4.27 P < 0.0001 NA
Test for subgroup differences P= 0.27 P= 0.0004 P= 0.90 P= 0.55 NA
NSC
Intraspinal
Patients (n) 33 33 20 4 2
Total (95% CI) −2.92 (−5.09, −0.76) −1.87 (−3.09, −0.65) −0.43 (−1.27, 0.40) −1.96 (−5.69, 1.77) −1.21 (−6.79, 4.37)
Test for overall effect;
Heterogeneity
Z= 2.65 P= 0.008
I2= 51%
Z= 3.00 P= 0.003
I2= 0%
Z= 1.02 P= 0.31
I2= 0%
Z= 1.03 P= 0.30
NA




Patients (n) 11 11 9 NA NA
Total (95% CI) −0.91 (−3.20, 1.38) 0.18 (−1.94, 2.30) 0.07 (−2.13, 2.27) NA NA
Test for overall effect;
Heterogeneity
Z= 0.78 P= 0.44
NA
Z= 0.17 P= 0.87
NA
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fluid vehicle appear the most promising. The rational to use MSCs
in ALS is based on their capacity to produce and release
neurotrophins30 and secrete molecules that can suppress the
activation and function of both the innate and adaptive immune
systems31. In ALS patients, increased numbers of CD4+ and CD8+
T cells and dendritic cells have been detected near dying
motoneurons in the spinal cord and in brain parenchyma32.
Preclinical studies have reported that human MSC transplantation
attenuates neuroinflammation, improves motor performance, and
extends survival in a mouse model of ALS33. In addition, it is
possible that mitochondrial transfer from MSCs can improve
bioenergetics of recipient cells34. However, a precise characteriza-
tion of the biodistribution of MSCs and definition of the
mechanism(s) of action is lacking. Since BM-MSCs were obtained
from the same patient in these trials, there was no need to
immunosuppress the patients. However, patient-derived SCs may
express genetic and epigenetic disease-related footprints, making
them unsuitable for therapeutic purposes35. Nevertheless BM-
MSCs from ALS patients have been reported to maintain the
cytokine secretory profile and to be more efficient in decreasing
TNF alpha—but also to respond differently to induction36 (some-
what questioning NurOwn® strategy)15,25.
Initially driven to achieve neuronal cell replacement, fetal NSCs
were embraced as a cell source that is renewable while being
inherently non-tumorigenic and with low immunogenicity37. None-
theless, NSCs appear more likely to differentiate into glial cells
(astrocytes and oligodendrocytes) and to provide trophic support to
dying motoneurons35. A toxic effect of astrocytes has been well
established in ALS spinal cord, therefore, providing healthy glia into
the area may have a positive impact on disease outcome. The fetal
NSCs used in these studies had different origins in the spinal
cord (Neuralstem Inc.)20,21 or forebrain22 which may define their
restorative capacity, as regional differences in glial cells are
becoming increasingly recognized38. Immunosuppression is also a
factor that needs to be considered when using allogeneic cells,
even if fetal NSCs appear to induce little immunogenicity39 and
survival has been documented after withdrawal of immunosup-
pression40. In that postmortem analysis, nests of transplanted spinal
NSCs were identified but did not show significant differentiation
into glia and only subsets were labeled for SOX2 or NeuN (a marker
of mature neurons)40. Indeed, protective mechanisms may be
Fig. 3 Effect of SC therapy on pulmonary function. Forest-plots of the changes in FVC, in points per month, between the lead-in period and
the follow-up values [(score at tx post− score at t0)/x] minus [(score at t0− score at tx pre)/x], evaluated at different time points in patients
infused with a MSCs or b NSCs. Squares and black lines represent the mean differences and 95% CI of individual studies and the different
colors stand for the follow-up time as indicated in the legend.
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mediated by the NSCs or by other cell types as Blanquer et al.
reported the presence of nests of MNC transplanted cells
surrounding motoneurons which showed less ubiquitin inclusions
and were more numerous at targeted levels (if only ~25% from
control)23. With currently available datasets, these three SC types
can only be compared in intraspinal administration, but the
observed effects are too small to draw any conclusion.
For any therapy, but in particular for those targeting the CNS,
because of the barriers and enclosures that protect it, delivery is
critical. For ALS, local delivery targeting the upper motoneurons
(intracortical), lower motoneurons (intraspinal), or neuromuscular
junction (intramuscular) requires invasive procedures and multiple
injections, each representing a risk of AEs, which, in particular, into
the CNS parenchyma may have serious consequences, and
therefore requires a careful risk–benefit analysis. Equally impor-
tant, with local approaches the cell distribution is rather restricted
to the injected segment or area (for example, with 20 intraspinal
injections only about 15% (8 cm) of the spinal cord area was
covered)41. This has to be taken into account when calculating the
cell dose because increasing the cell number without increasing
their spread could be detrimental.
On the other end, systemic (intravenous) delivery of MSCs while
convenient from a logistic point of view has been found to be
mostly ineffective42.
Thus, intrathecal delivery by injection into the subarachnoid
space presents the most favorable profile, achieving a broader
distribution and, possibly, penetration in the parenchyma through
paravascular spaces, while using relatively minor invasive proce-
dures. This route makes it feasible to repeat the administration
and to perform a sham procedure allowing to evaluate separately
the effect of the procedure and that of the SC product (although in
this case all trials that used the intrathecal route were done with
BM-MSCs so it is not possible to completely separate the effect of
both variables on the outcome). A more recently proposed infusion
into the subpial space41 appears promising in preclinical models,
by achieving a broad distribution of infused cells, but requires
surgery making more problematic to repeat the administration.
Given that the effect on the clinical progression appears to be
transient, an invasive procedure would not be desirable.
A compelling lesson learned from previous research is that
confirmatory trials of the efficacy of new SC lines for the treatment
of ALS should be initiated only after an evidence-based treatment
protocol is constructed. There are distinct challenges and
opportunities in performing early-phase SC therapy trials in ALS,
which require special approaches and unique trial designs. The
current stage of the clinical research in this field requires to
identify a primary outcome measure which can show an
improvement that is clinically meaningful to the patient so that
the risk of the procedure is reasonably balanced by the potential
clinical benefits and the value of the resulting scientific knowl-
edge. Investigators should choose to stratify for factors most
relevant to the outcome measure of the trial. Patient selection is a
very important variable, but to date, there is little agreement
about inclusion criteria. A more heterogeneous study population
may mask efficacy of the study intervention on specific
subpopulations of patients bearing genetic forms of the disease
or restricted phenotypes. According to the updated guidelines for
ALS clinical trial design43, responder analyses should be included,
having the potential to demonstrate beneficial effects of a
proposed treatment on a subset of patients with a shared unique
Fig. 4 Effects of cell type and delivery on outcomes. Violin plots showing the effect of a the cell product and b the administration route, on
the differences between ALSFRS-R and FVC slopes calculated for the lead-in period (pre) and the follow-up time points, as indicated. Points
represent individual studies. Discontinued lines represent the mean value. Two-way ANOVA with post-hoc Tukey’s test, *P ≤ 0.05. IS intraspinal,
IT intrathecal, IV intravascular, mo month.
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phenotype. Moreover, in designing and implementing ALS SC
clinical trials, investigators should incorporate predictive biomar-
kers, prognostic biomarkers, and, especially biomarkers of SC
activity.
Overall, based on current evidence, we can conclude that SC
therapy may have a positive, if transient, effect on ALS
progression, but not on the pulmonary function, and that both
the cell product and the delivery route need to be carefully
reconsidered and optimized in adequately controlled preclinical
models before moving forward in ALS patients. Furthermore, for a
SC therapy to be successful, a third factor, the recipient, needs
also to be integrated in the equation. Illustrating this point,
the results of NurOwn® Phase III trial (NCT03280056) in which
patients received three intrathecal injections of autologous pre-
conditioned BM-MSCs or placebo were released last month. The
trial did not meet the endpoint but analysis of a subgroup of
early patients showed the anticipated difference between treated
and placebo groups. The company has announced initiation of
expanded access program (compassionate use) for some patients
who completed the clinical trial and meet specific eligibility criteria
(https://ir.brainstorm-cell.com/2020-11-17-BrainStorm-Announces-
Topline-Results-from-NurOwn-R-Phase-3-ALS-Study). Thus, a better
understanding of disease mechanisms in individual patients would
greatly enhance the possibility to implement the most suitable SC
strategy to modify the prognosis of ALS patients.
METHODS
Search strategy and selection criteria
This systematic review and meta-analysis is reported according to the
PRISMA statement. We comprehensively searched for full-text published
studies with no publication date restriction. Studies reporting data related to
the administration of human SCs for the treatment of patients with ALS
were identified using MEDLINE. The last search was carried out on June 30,
2020. The search strategy is detailed in Supplementary Table 1. Only full-text
clinical studies published in English, containing data for ALSFRS and/or FVC,
were included. We excluded meta-analysis and reviews, and case reports.
Data extraction and quality assessment
Study selection was performed by C.M-T, G.A., and R.S-P, examining
independently the full text of potentially relevant studies and applying
eligibility criteria to select the included studies, by consensus. Eligibility
criteria included reporting numerical data for relevant outcomes, ALSFRS
and/or FVC, for at least three time points: tpre, at ≥3 ± 0.5 months before
the intervention, t0, at the time of the intervention (0 ≤ 0.5 months), and
tpost, at ≥3 months following the intervention, in order to calculate the
scores for the lead-in and follow-up periods. Information obtained from
these studies enclosed inclusion criteria, a description of the patients,
characteristics of the administered treatment, and the outcomes. Com-
munication with the author of the included studies was established in
cases of doubt or to request additional data. C.M-T. extracted the outcome
data from the included studies and G.A. and R.S-P. revised the extracted
data. Disagreements were solved by discussion and consensus between
the authors. To evaluate the methodological quality of the included
studies, we employed the risk of bias assessment tool for non-randomized
studies (RoBANS)10, since most of the included studies were non-
randomized. Note that not all patients who participated in one of the 11
included studies had sufficient data to be used in the meta-analysis and
slope calculations. Actual numbers are provided in Tables 2 and 3.
Outcomes
The following outcomes were assessed: (1) ALSFRS-R and (2) FVC, before
and after treatment, and (3) incidence of AEs.
Statistical analysis
We carried out the statistical analysis using Review Manager 5.3 (RevMan
5.3). Each data point is a study (not a patient). Subgroup analyses included
cell type and administration route. Mean differences, SD, and 95%
confidence interval (CI) were calculated for changes in the monthly rate of
decline of ALSFRS-R and FVC between the lead-in period and the follow-up
periods for each patient. The scores (mean and SD) collected as ALSFRS
were normalized and recalculated for a 48-point scale, in order to analyze
together the point-per-month and slopes for all studies. We used inverse-
variance to estimate the intervention effect. Random-effects model was
used to consider the differences between individual study effects to
estimate the treatment effect. Between-study variance was calculated
using the DerSimonian–Laird method44. The heterogeneity between
studies was assessed using I2 test. Funnel plots and Egger’s test were
employed to assess publication bias45 using dmetar package in R v4.0.3.
Non-linear regression (least squares fit) was used to calculate the pre-
and post-treatment slopes for ALSFRS-R and FVC from all available data
points of individual studies (mean and SD). Two-way analysis of variance
(ANOVA) tests grouped by cell product or route of delivery were used to
compare the effects of the intervention on the slopes at different times,
followed by post-hoc Tukey’s multiple comparisons test. These analyses
were performed using GraphPad Prism v8.4.3. Statistical significance was
considered when P ≤ 0.05.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Aggregated data used in the study are available from the corresponding author upon
reasonable request.
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